These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 23727750)

  • 1. Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response.
    Robles M; Vigouroux S; Tabrizi R; Bouabdallah K; Dilhuydy MS; Parrens M; Leguay T; Pigneux A; Dumas PY; Lascaux A; Duclos C; Marit G; Milpied N
    Bone Marrow Transplant; 2013 Nov; 48(11):1484-5. PubMed ID: 23727750
    [No Abstract]   [Full Text] [Related]  

  • 2. Sustained response after reduced-intensity conditioning allogeneic stem cell transplantation for patients with relapsed peripheral T-cell non-Hodgkin lymphoma.
    de Lavallade H; Cassier PA; Bouabdallah R; El-Cheikh J; Faucher C; Fürst S; Coso D; Sainty D; Arnoulet C; Gastaut JA; Chetaille B; Xerri L; Blaise D; Mohty M
    Br J Haematol; 2008 Sep; 142(5):848-50. PubMed ID: 18631344
    [No Abstract]   [Full Text] [Related]  

  • 3. High-dose therapy and stem cell transplantation.
    Zinzani PL
    Semin Hematol; 2010 Apr; 47 Suppl 1():S15-7. PubMed ID: 20359581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
    Shustov A
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma.
    Dreger P; Laport GG
    Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):100-7. PubMed ID: 18162229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
    Dodero A; Spina F; Narni F; Patriarca F; Cavattoni I; Benedetti F; Ciceri F; Baronciani D; Scimè R; Pogliani E; Rambaldi A; Bonifazi F; Dalto S; Bruno B; Corradini P
    Leukemia; 2012 Mar; 26(3):520-6. PubMed ID: 21904377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic transplant for peripheral T-cell lymphoma: a sparkle of hope and many questions.
    Ramsdale E; Van Besien K
    Leuk Lymphoma; 2011 Aug; 52(8):1415-7. PubMed ID: 21599586
    [No Abstract]   [Full Text] [Related]  

  • 8. Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.
    Corradini P; Dodero A; Zallio F; Caracciolo D; Casini M; Bregni M; Narni F; Patriarca F; Boccadoro M; Benedetti F; Rambaldi A; Gianni AM; Tarella C
    J Clin Oncol; 2004 Jun; 22(11):2172-6. PubMed ID: 15169805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hematopoietic SCT for peripheral T-cell lymphoma.
    Gutiérrez A; Caballero MD; Pérez-Manga G; Rodriguez J
    Bone Marrow Transplant; 2008 Dec; 42(12):773-81. PubMed ID: 18936735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a role for hemopoietic stem-cell transplantation in CTCL?
    Dearden C
    Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):24-8. PubMed ID: 17474356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method.
    Gutiérrez-Aguirre CH; Ruiz-Argüelles G; Cantú-Rodríguez OG; González-Llano O; Jaime-Pérez JC; García-Rodríguez F; López-Otero A; Herrera-Garza JL; Gómez-Almaguer D
    Ann Hematol; 2010 Oct; 89(10):1045-52. PubMed ID: 20490794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current state of art for transplantation paradigms in peripheral T-cell lymphomas.
    Perrone G; Farina L; Corradini P
    Expert Rev Hematol; 2013 Aug; 6(4):465-74. PubMed ID: 23991932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of stem cell transplantation.
    Harousseau JL
    Hematol Oncol Clin North Am; 2007 Dec; 21(6):1157-74, x. PubMed ID: 17996593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of peripheral T-cell lymphomas (PTCL) with high-dose chemotherapy and autologous or allogeneic hematopoietic transplantation.
    Kahl C; Leithäuser M; Wolff D; Steiner B; Hartung G; Casper J; Freund M
    Ann Hematol; 2002 Nov; 81(11):646-50. PubMed ID: 12454703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic hematopoietic stem cell transplantation in adolescent and adult patients with high-risk T cell acute lymphoblastic leukemia.
    Bakr M; Rasheed W; Mohamed SY; Al-Mohareb F; Chaudhri N; Al-Sharif F; Al-Zahrani H; Al-Dawsari G; Saleh AJ; Nassar A; Ahmed S; Elghazaly A; Ahmed SO; Ibrahim K; Chebbo W; El Gohary GM; Al Mahayni MH; Hussain F; Nurgat Z; Elhassan TA; Walter CU; Aljurf M
    Biol Blood Marrow Transplant; 2012 Dec; 18(12):1897-904. PubMed ID: 22824185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The outcome of reduced intensity allogeneic stem cell transplantation and autologous stem cell transplantation when performed as a first transplant strategy in relapsed follicular lymphoma: an analysis from the Lymphoma Working Party of the EBMT.
    Robinson SP; Canals C; Luang JJ; Tilly H; Crawley C; Cahn JY; Pohlreich D; Le Gouill S; Gilleece M; Milpied N; Attal M; Biron P; Maury S; Rambaldi A; Maertens J; Capria S; Colombat P; Montoto S; Sureda A
    Bone Marrow Transplant; 2013 Nov; 48(11):1409-14. PubMed ID: 23771004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplantation in the Treatment of Primary Cutaneous Aggressive Epidermotropic Cytotoxic CD8-Positive T-Cell Lymphoma.
    Cyrenne BM; Gibson JF; Subtil A; Girardi M; Isufi I; Seropian S; Foss F
    Clin Lymphoma Myeloma Leuk; 2018 Jan; 18(1):e85-e93. PubMed ID: 29223388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced toxicity conditioning and allogeneic stem cell transplantation in adults using fludarabine, carmustine, melphalan, and antithymocyte globulin: outcomes depend on disease risk index but not age, comorbidity score, donor type, or human leukocyte antigen mismatch.
    Slack JL; Dueck AC; Fauble VD; Sproat LO; Reeder CB; Noel P; Khera N; Betcher JA; Klein JL; Leis JF; Adams RH
    Biol Blood Marrow Transplant; 2013 Aug; 19(8):1167-74. PubMed ID: 23664940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome after reduced-intensity conditioning allogeneic SCT for AML in first complete remission: comparison of two regimens.
    Cahu X; Mohty M; Faucher C; Chevalier P; Vey N; El-Cheikh J; Guillaume T; Furst S; Delaunay J; Ayari S; Moreau P; Gastaut JA; Harousseau JL; Blaise D
    Bone Marrow Transplant; 2008 Nov; 42(10):689-91. PubMed ID: 18679370
    [No Abstract]   [Full Text] [Related]  

  • 20. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study.
    Feyler S; Prince HM; Pearce R; Towlson K; Nivison-Smith I; Schey S; Gibson J; Patton N; Bradstock K; Marks DI; Cook G
    Bone Marrow Transplant; 2007 Sep; 40(5):443-50. PubMed ID: 17589529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.